Insulin glargine in a Brazilian State : an assessment of drug utilization, effectiveness and value to provide future direction

Tools

Godman, Brian and de Souza, Ana Luísa Caires and de Assis Acurcio, Francisco and Guerra Júnior, Augusto Afonso (2014) Insulin glargine in a Brazilian State : an assessment of drug utilization, effectiveness and value to provide future direction. In: II International Symposium on Pharmacoeconomics in SUS – “Health Technologies Assessment”, 2014-11-10 - 2014-11-13, Brazil.

[thumbnail of Godman-etal-ISPSUS-2014-Insulin-glargine-in-a-Brazilian-State-an-assessment-of-drug-utilization]
Preview
 Text. Filename: Godman_etal_ISPSUS_2014_Insulin_glargine_in_a_Brazilian_State_an_assessment_of_drug_utilization.pdf
Accepted Author Manuscript
Download (161kB)| Preview

Abstract

The cost and utilisation of the insulin analogue (Insulin glargine) has grown appreciably in the State of Minas Gerais in Brazil in recent years, with costs growing on average by 291% per year. This growth has been driven by an increasing number of successful law suits and a 536% price differential between insulin glargine and neutral protamine Hagedorn (NPH) insulin. One way forward to address concerns with its growing utilisation is to undertake a systematic review assessing the efficacy and safety of insulin glargine compared with NPH insulin in patients with Type I diabetes. As a result, provide published data to support future recommended activities by the State to limit its use.

CORE (COnnecting REpositories)